Plasmid DNA Manufacturing Market Revenue to Cross US$ 539 million by 2035

Published: February 2024


According to a recently published report by Roots Analysis, the growing pipeline of advanced therapeutic medicinal product and an increase in the demand for plasmid DNA is driving the plasmid DNA manufacturing market growth

Plasmid DNA Manufacturing Industry Overview

The global plasmid DNA manufacturing market is anticipated to grow at a CAGR of 14.85% from 2023-2035, reaching USD 539 million by 2035.

Plasmid DNA, which is a circular, double-stranded molecule capable of autonomous replication separate from the chromosomal DNA, plays a crucial role in the development and manufacturing of cell and gene therapies as well as nucleic acid vaccines. Consequently, the demand for plasmid DNA is experiencing rapid growth, particularly driven by the expanding pipeline of cell and gene therapies. In addition, prominent pharmaceutical players, including Moderna and Pfizer-BioNTech have employed plasmid-based platforms for their mRNA vaccines, resulting in an increased demand. However, the production of plasmids encounters several obstacles, including limited yield, plasmid instability, and stringent regulatory oversight. Therefore, drug developers are increasingly relying on third-party service providers with specialized expertise in plasmid DNA manufacturing to overcome the aforementioned challenges. These service providers offer comprehensive support ranging from process development, optimization, plasmid construction, design, and engineering, to GMP-grade manufacturing. Additionally, they contribute to streamlining the manufacturing process, optimizing resource utilization, and ensuring the provision of plasmid DNA of superior quality that complies with regulatory and research standards.

To order this 300+ page report, which features 125+ figures and 180+ tables, please visit https://www.rootsanalysis.com/reports/plasmid-dna-manufacturing-market.html

Market Drivers

Various factors contribute to the plasmid DNA manufacturing market growth. These factors include growing demand for gene therapies, increased investment in nucleic acid-based vaccine development and advancements in gene editing technology. The recognition of gene therapies as a promising treatment approach for genetic and oncological disorders has increased the demand for reliable and efficient production of plasmid DNA, which serves as a vector for these therapies. Additionally, the rising adoption of nucleic acid vaccines has led to increased investment in vaccine research and development, driving the demand for plasmid DNA as a crucial component of RNA/DNA vaccines. Furthermore, advancements in gene editing technology, such as CRISPR-Cas9, are expected to enhance the efficiency and safety of plasmid production, contributing to the market's growth.

Market Restraints

One of the primary restraints in this industry is the high cost of establishing facilities and installing sophisticated equipment required for plasmid DNA manufacturing. Additionally, the ongoing maintenance of such dedicated facilities and equipment requires substantial capital investment. These costs create significant barriers to entry for new entrants, limiting competition and potentially hindering overall industry growth. Furthermore, the evolving regulatory guidelines may reclassify plasmid manufacturers from starting material producers to drug substance suppliers, leading to stricter inspections and oversight. This increased scrutiny poses challenges for compliance and meeting regulatory requirements in a cost effective and timely manner.

Growth Factors

Despite the challenges, several growth factors continue to drive the plasmid DNA manufacturing market forward. One notable factor is the emergence of new markets, specifically in China and India, which have a large patient population and a rising demand for biologics and gene therapies. As investments in these markets increase, it is expected that opportunities for plasmid DNA manufacturing service providers will also grow. Moreover, stakeholders in the industry can leverage strategic partnerships to enhance their existing service portfolios. Such collaborations not only facilitate market reach expansion but also enable manufacturers to broaden their customer base. In addition, the integration of novel technologies by CMOs and CDMOs can significantly enhance their manufacturing services. By incorporating unique features and characteristics, such organizations can differentiate themselves in the market, allowing them to vary the prices of their offerings.

Plasmid DNA Manufacturing Market Segments

Based on the scale of operation, the market is segmented into Commercial, Clinical, and Preclinical.

  • The clinical segment led the plasmid DNA manufacturing market, capturing the largest revenue share of more than 55.0% in 2023.
  • The commercial segment is anticipated to show the highest market growth potential during the forecast period of over 21% annually.

Based on the grade of plasmid DNA, the market is segmented into GMP Grade Plasmid DNA, High Quality Plasmid DNA, and Research Grade Plasmid DNA.

  • The GMP grade plasmid DNA segment led the plasmid DNA manufacturing market, capturing the largest revenue share of more than 94.0% in 2023.
  • The high-quality Plasmid DNA segment is anticipated to show the highest market growth potential during the forecast period of over 17% annually.

Based on the application area, the market is segmented into DNA Vaccine Development, Cell Therapy Manufacturing, Gene Therapy Manufacturing, mRNA Vaccine Development, and Viral Vector Manufacturing.

  • The gene therapy manufacturing segment led the market, capturing the largest revenue share of close to 60.0% in 2023.
  • The DNA vaccine development segment is anticipated to show the highest market growth potential during the forecast period of over 19% annually.

Based on the therapeutic area, the market is segmented into Genetic Disorders, Infectious Diseases, Oncological Disorders, and Others.

  • The oncological disorders segment led the plasmid DNA manufacturing market, capturing the largest revenue share of more than 35.0% in 2023.
  • In fact, the oncological disorders segment is anticipated to demonstrate lucrative growth during the forecast period.

Based on the end user, the market is segmented into Pharma / Biotech Companies, Academic and Research Institutes and Other End Users.

  • The pharma / biotech segment led the plasmid DNA manufacturing market, capturing the largest revenue share of close to 81.0% in 2023.
  • The academic and research institutes segment is anticipated to show the highest market growth potential during the forecast period of over 15% annually.

Based on the Regional Insights, the market is segmented into North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of The World.

  • North America dominated the market and accounted for the largest revenue share of over 44.0% in 2023.
  • In Asia, the plasmid DNA manufacturing market is anticipated to demonstrate lucrative growth during the forecast period.

Key Companies Profiled

The plasmid DNA manufacturing market report also includes detailed profiles of key players (listed below) that offer plasmid DNA manufacturing services:

  • AGC Biologics
  • Aldevron
  • Catalent Pharma Solutions
  • Centre for Breakthrough Medicine
  • Charles River
  • GenScript ProBio
  • PackGene Biotech
  • Thermo Fisher Scientific
  • VectorBuilder
  • VGXI
  • Wuxi AppTec

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/plasmid-dna-manufacturing-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry